Molecular diagnostics
Our Molecular Oncology Laboratory integrates advanced molecular diagnostics with clinical and translational expertise to deliver actionable insights for precision oncology. Our multidisciplinary team of molecular scientists and pathologists operates in an ISO 15189-accredited environment, using state-of-the-art technologies to support diagnosis, treatment decisions and clinical trial enrollment.
We specialize in comprehensive genomic and transcriptomic profiling across tissue and liquid biopsy, enabling the detection of clinically relevant alterations that drive tumor progression and therapeutic response.
CORE CAPABILITIES:
- Mutation analysis in tissue and liquid biopsy
- Gene amplification and translocation testing
- Immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH)
- Gene expression profiling and transcriptomic signatures
- Tumor mutational burden (TMB) and microsatellite instability (MSI) assessment
KEY TECHNOLOGIES & PLATFORMS:
- TSO500 v2 panel in NextSeq1000 (Illumina) for comprehensive genomic profiling (500+ genes, TMB, MSI, RNA fusions)
- Ncounter (Nanostring) for gene expression profiling and transcriptomic signatures
- PROSIGNA (PAM50) for breast cancer risk stratification
- Miseq (Illumina) for targeted NGS panels
- IDYLLA (Biocartis) for rapid, automated molecular testing
- Rotor-Gene (Qiagen) and QuantStudio (Applied Biosystem) for qPCR-based assays
- Ventana (Roche) platforms for IHC
Comprehensive Genomic Profiling – TSO500 v2 (NEW):
PANGAEA has recently incorporated the TSO500 v2 (Illumina) platform, marking a major milestone in our molecular diagnostics capabilities and reinforcing our position at the forefront of precision oncology.
This advanced next-generation sequencing (NGS) solution enables comprehensive genomic profiling in a single assay, providing deep molecular insights to guide clinical decision-making and accelerate drug development.
Why TSO500 v2 matters
Simultaneous detection of:
Single nucleotide variants (SNVs)
Insertions and deletions (indels)
Copy number variations (CNVs)
Gene fusions (RNA)
Analysis of 500+ cancer-related genes
Integrated biomarkers:
Tumor Mutational Burden (TMB)
Microsatellite Instability (MSI)
One test. Hundreds of genes. Infinite possibilities in precision oncology.
RAPID MOLECULAR TESTING – IDYLLA PLATFORM
We have incorporated the IDYLLA platform to provide fast and reliable molecular diagnostics with minimal hands-on time.
Our portfolio includes a rapid POLE mutation detection test, enabling the identification of POLE/POLD1 alterations in just a few days, supporting clinical decision-making in tumors such as endometrial and colorectal cancer.
liquid biopsy
We offer highly sensitive liquid biopsy solutions based on blood-derived samples, enabling:
Non-invasive tumor profiling
Real-time monitoring of treatment response
Early detection of resistance mechanisms
This approach overcomes limitations associated with tissue availability and enables longitudinal patient monitoring in precision oncology
PANGAEA is one of the leading European providers in liquid biopsy and the first pharmacogenomics laboratory in Spain accredited by ENAC (ISO 15189, nº 750/LE1556) for genetic testing in liquid biopsy samples.
Regulatory compliance (IVDR Art. 5.5) Pangaea Oncology publishes its public declaration on the use of laboratory-developed tests. View declaration.
- We also provide our molecular diagnostic services to pharmaceutical industry.
- We also provide our molecular diagnostic services to pharmaceutical industry.
Our experience is endorsed by the numerous clinical trials in which we were selected as a reference laboratory.